Telik kept at sell by Merrill

Merrill Lynch analyst Eric Ende maintained Telik Inc. at sell. Enrollment in the company's Assist-3 trial of Telcyta in second-line ovarian cancer was completed, about six months later than expected. Data may not be available until the fourth quarter of 2006, later than prior guidance of second or third quarter. Shares of the Palo Alto, Calif., biopharmaceutical company were down 17 cents, or 0.91%, at $18.44 on volume of 638,493 shares versus the three-month running average of 838,710 shares. (Nasdaq: TELK)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.